[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "",
    "text": "Reference Papers:\n\nAlhuarrat et al. 2023\nKhan et al. 2024\nSalman et al. 2025\n\nStudy Objective: To compare in-hospital outcomes and complications between Leadless Pacemakers and Traditional Transvenous (TV-VVI) Pacemakers among patients with Chronic Kidney Disease (CKD) undergoing pacemaker implantation in U.S. hospitals from 2018 to 2020, adjusting for demographic, socioeconomic, clinical (including CKD stage), and hospital-related factors.\nData Source: Cross-sectional analysis using the National Inpatient Sample (NIS) database from 2018 to 2020, a representative sample of all-payer inpatient hospitalizations in the U.S.\nPatient Selection: Included all inpatient admissions for patients 18 years or older with a diagnosis of Chronic Kidney Disease (CKD), identified using ICD-10 diagnosis codes. From this cohort, patients who underwent implantation of either a Leadless Pacemaker or a Traditional Transvenous (TV-VVI) Pacemaker, identified using ICD-10-PCS procedure codes, were included. Patients were then categorized into two groups based on the type of pacemaker received: Leadless Pacemaker or Traditional Transvenous Pacemaker.\nOutcomes of Interest:\n\nIn-hospital Mortality\nLength of Stay (days)\nInflation-adjusted Total Charge ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\nAcute Kidney Injury (AKI)\nAny Complication (including vascular, pericardial, pneumothorax, infectious, or device-related complications)\n\nStatistical Analysis: Univariable and multivariable analyses were conducted to evaluate the association between pacemaker type (Leadless vs. Traditional Transvenous) and inpatient outcomes within the CKD patient cohort:\n\nUnivariable Analysis:\n\nContinuous variables: Design-based Kruskal-Wallis test.\nCategorical variables: Pearson’s X² test with Rao & Scott adjustment to account for survey design.\n\nMultivariable Analysis:\n\nLogistic regression for binary outcomes (e.g., in-hospital mortality, AKI).\nLinear regression for continuous outcomes (e.g., length of stay, total charges).\n\nAdjustments: Models controlled for the following covariates:\n\nDemographics and Socioeconomic Factors: Age, Sex, Race, Residential income, Expected primary payer.\nClinical Factors: Charlson comorbidity index, Admission Type, Chronic Kidney Disease Stage, Hypertension, Diabetes Mellitus, Obesity, Chronic Pulmonary Disease, Liver Disease, Peripheral Vascular Disease, Congestive Heart Failure, Myocardial Infarction.\nHospital-Level Factors: Hospital region, Hospital bedsize, Hospital location and teaching status.\n\n\nSoftware: All statistical analyses were performed using R Statistical Language (Version 4.5.0; R Foundation for Statistical Computing, Vienna, Austria), incorporating survey-weighted procedures via the survey package to account for the complex sampling design of NIS."
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "",
    "text": "Reference Papers:\n\nAlhuarrat et al. 2023\nKhan et al. 2024\nSalman et al. 2025\n\nStudy Objective: To compare in-hospital outcomes and complications between Leadless Pacemakers and Traditional Transvenous (TV-VVI) Pacemakers among patients with Chronic Kidney Disease (CKD) undergoing pacemaker implantation in U.S. hospitals from 2018 to 2020, adjusting for demographic, socioeconomic, clinical (including CKD stage), and hospital-related factors.\nData Source: Cross-sectional analysis using the National Inpatient Sample (NIS) database from 2018 to 2020, a representative sample of all-payer inpatient hospitalizations in the U.S.\nPatient Selection: Included all inpatient admissions for patients 18 years or older with a diagnosis of Chronic Kidney Disease (CKD), identified using ICD-10 diagnosis codes. From this cohort, patients who underwent implantation of either a Leadless Pacemaker or a Traditional Transvenous (TV-VVI) Pacemaker, identified using ICD-10-PCS procedure codes, were included. Patients were then categorized into two groups based on the type of pacemaker received: Leadless Pacemaker or Traditional Transvenous Pacemaker.\nOutcomes of Interest:\n\nIn-hospital Mortality\nLength of Stay (days)\nInflation-adjusted Total Charge ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\nAcute Kidney Injury (AKI)\nAny Complication (including vascular, pericardial, pneumothorax, infectious, or device-related complications)\n\nStatistical Analysis: Univariable and multivariable analyses were conducted to evaluate the association between pacemaker type (Leadless vs. Traditional Transvenous) and inpatient outcomes within the CKD patient cohort:\n\nUnivariable Analysis:\n\nContinuous variables: Design-based Kruskal-Wallis test.\nCategorical variables: Pearson’s X² test with Rao & Scott adjustment to account for survey design.\n\nMultivariable Analysis:\n\nLogistic regression for binary outcomes (e.g., in-hospital mortality, AKI).\nLinear regression for continuous outcomes (e.g., length of stay, total charges).\n\nAdjustments: Models controlled for the following covariates:\n\nDemographics and Socioeconomic Factors: Age, Sex, Race, Residential income, Expected primary payer.\nClinical Factors: Charlson comorbidity index, Admission Type, Chronic Kidney Disease Stage, Hypertension, Diabetes Mellitus, Obesity, Chronic Pulmonary Disease, Liver Disease, Peripheral Vascular Disease, Congestive Heart Failure, Myocardial Infarction.\nHospital-Level Factors: Hospital region, Hospital bedsize, Hospital location and teaching status.\n\n\nSoftware: All statistical analyses were performed using R Statistical Language (Version 4.5.0; R Foundation for Statistical Computing, Vienna, Austria), incorporating survey-weighted procedures via the survey package to account for the complex sampling design of NIS."
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 126,0151\nTV-VVI\nN = 115,5201\nLeadless Pacemaker\nN = 10,4951\np-value2\n\n\n\n\nAge, y\n78 (10)\n78 (10)\n76 (11)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n0.005\n\n\n    Female\n54,970 (44%)\n50,695 (44%)\n4,275 (41%)\n\n\n\n\n    Male\n71,040 (56%)\n64,825 (56%)\n6,215 (59%)\n\n\n\n\nRace\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n92,175 (75%)\n85,060 (75%)\n7,115 (70%)\n\n\n\n\n    Asian or Pacific Islander\n3,865 (3.1%)\n3,425 (3.0%)\n440 (4.3%)\n\n\n\n\n    Black\n13,740 (11%)\n12,325 (11%)\n1,415 (14%)\n\n\n\n\n    Hispanic\n9,960 (8.1%)\n9,005 (8.0%)\n955 (9.3%)\n\n\n\n\n    Native American\n670 (0.5%)\n610 (0.5%)\n60 (0.6%)\n\n\n\n\n    Other\n2,710 (2.2%)\n2,460 (2.2%)\n250 (2.4%)\n\n\n\n\nResidential income\n\n\n\n\n\n\n0.7\n\n\n    $1 - $51,999\n32,460 (26%)\n29,655 (26%)\n2,805 (27%)\n\n\n\n\n    $52,000 - $65,999\n33,165 (27%)\n30,475 (27%)\n2,690 (26%)\n\n\n\n\n    $66,000 - $87,999\n31,775 (26%)\n29,160 (26%)\n2,615 (25%)\n\n\n\n\n    $88,000 or more\n26,900 (22%)\n24,640 (22%)\n2,260 (22%)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n0.094\n\n\n    Private\n10,140 (8.1%)\n9,385 (8.1%)\n755 (7.2%)\n\n\n\n\n    Medicaid\n3,825 (3.0%)\n3,425 (3.0%)\n400 (3.8%)\n\n\n\n\n    Medicare\n108,720 (86%)\n99,645 (86%)\n9,075 (87%)\n\n\n\n\n    Other\n3,220 (2.6%)\n2,965 (2.6%)\n255 (2.4%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n0.13\n\n\n    Midwest\n31,920 (25%)\n29,550 (26%)\n2,370 (23%)\n\n\n\n\n    Northeast\n22,310 (18%)\n20,375 (18%)\n1,935 (18%)\n\n\n\n\n    South\n46,020 (37%)\n42,095 (36%)\n3,925 (37%)\n\n\n\n\n    West\n25,765 (20%)\n23,500 (20%)\n2,265 (22%)\n\n\n\n\nHospital bedsize\n\n\n\n\n\n\n&lt;0.001\n\n\n    Large\n70,740 (56%)\n63,815 (55%)\n6,925 (66%)\n\n\n\n\n    Medium\n35,220 (28%)\n32,780 (28%)\n2,440 (23%)\n\n\n\n\n    Small\n20,055 (16%)\n18,925 (16%)\n1,130 (11%)\n\n\n\n\nHospital location and teaching status\n\n\n\n\n\n\n&lt;0.001\n\n\n    Rural\n6,010 (4.8%)\n5,775 (5.0%)\n235 (2.2%)\n\n\n\n\n    Urban, non-teaching\n21,875 (17%)\n20,600 (18%)\n1,275 (12%)\n\n\n\n\n    Urban, teaching\n98,130 (78%)\n89,145 (77%)\n8,985 (86%)\n\n\n\n\nCharlson comorbidity index\n4.67 (1.64)\n4.65 (1.63)\n4.95 (1.69)\n&lt;0.001\n\n\nAdmission Type\n\n\n\n\n\n\n0.3\n\n\n    Elective\n16,670 (13%)\n15,355 (13%)\n1,315 (13%)\n\n\n\n\n    Non-elective\n109,170 (87%)\n100,000 (87%)\n9,170 (87%)\n\n\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n&lt;0.001\n\n\n    CKD, Stage 1\n550 (0.5%)\n510 (0.6%)\n40 (0.5%)\n\n\n\n\n    CKD, Stage 2\n6,170 (6.1%)\n5,840 (6.3%)\n330 (3.7%)\n\n\n\n\n    CKD, Stage 3\n63,745 (63%)\n59,820 (65%)\n3,925 (44%)\n\n\n\n\n    CKD, Stage 4\n14,720 (15%)\n13,620 (15%)\n1,100 (12%)\n\n\n\n\n    CKD, Stage 5\n1,130 (1.1%)\n985 (1.1%)\n145 (1.6%)\n\n\n\n\n    ESRD\n14,940 (15%)\n11,610 (13%)\n3,330 (38%)\n\n\n\n\nHypertension\n119,280 (95%)\n109,440 (95%)\n9,840 (94%)\n0.061\n\n\nDiabetes Mellitus\n65,895 (52%)\n60,295 (52%)\n5,600 (53%)\n0.3\n\n\nObesity\n27,215 (22%)\n25,100 (22%)\n2,115 (20%)\n0.091\n\n\nChronic Pulmonary Disease\n32,125 (25%)\n29,250 (25%)\n2,875 (27%)\n0.034\n\n\nLiver Disease\n6,085 (4.8%)\n5,275 (4.6%)\n810 (7.7%)\n&lt;0.001\n\n\nPeripheral Vascular Disease\n16,405 (13%)\n14,995 (13%)\n1,410 (13%)\n0.6\n\n\nCongestive Heart Failure\n75,085 (60%)\n67,900 (59%)\n7,185 (68%)\n&lt;0.001\n\n\nMyocardial Infarction\n26,150 (21%)\n23,970 (21%)\n2,180 (21%)\n&gt;0.9\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment"
  },
  {
    "objectID": "quarto/index.html#univariable-analysis",
    "href": "quarto/index.html#univariable-analysis",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "Univariable Analysis:",
    "text": "Univariable Analysis:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 126,0151\nTV-VVI\nN = 115,5201\nLeadless Pacemaker\nN = 10,4951\np-value2\n\n\n\n\nDied during hospitalization\n3,140 (2.5%)\n2,550 (2.2%)\n590 (5.6%)\n&lt;0.001\n\n\nLength of stay (days)\n5 (3, 9)\n5 (3, 8)\n7 (4, 13)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n107,480 (67,447, 186,609)\n102,977 (65,598, 178,680)\n159,100 (105,158, 269,140)\n&lt;0.001\n\n\nAcute Kidney Injury\n58,990 (47%)\n54,360 (47%)\n4,630 (44%)\n0.012\n\n\nAny Complication\n12,390 (9.8%)\n10,420 (9.0%)\n1,970 (19%)\n&lt;0.001\n\n\nVascular Complication\n1,235 (1.0%)\n980 (0.8%)\n255 (2.4%)\n&lt;0.001\n\n\nPericardial Complication\n2,935 (2.3%)\n2,445 (2.1%)\n490 (4.7%)\n&lt;0.001\n\n\nPneumothorax Complication\n2,110 (1.7%)\n2,015 (1.7%)\n95 (0.9%)\n0.004\n\n\nInfectious Complication\n230 (0.2%)\n150 (0.1%)\n80 (0.8%)\n&lt;0.001\n\n\nDevice Complication\n7,000 (5.6%)\n5,740 (5.0%)\n1,260 (12%)\n&lt;0.001\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nIn-hospital Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nPacemaker Type\n\n\n\n\n\n\n\n\n    TV-VVI\n—\n—\n\n\n\n\n    Leadless Pacemaker\n1.83\n1.41, 2.37\n&lt;0.001\n\n\nAge, y\n1.01\n1.0, 1.02\n0.3\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.72\n0.60, 0.87\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.84\n0.51, 1.39\n0.5\n\n\n    Black\n0.96\n0.72, 1.28\n0.8\n\n\n    Hispanic\n0.89\n0.64, 1.24\n0.5\n\n\n    Native American\n0.56\n0.12, 2.49\n0.4\n\n\n    Other\n0.82\n0.44, 1.53\n0.5\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.81\n0.62, 1.06\n0.13\n\n\n    $66,000 - $87,999\n0.98\n0.76, 1.27\n&gt;0.9\n\n\n    $88,000 or more\n0.83\n0.63, 1.10\n0.2\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.32\n0.74, 2.33\n0.3\n\n\n    Medicare\n1.14\n0.78, 1.66\n0.5\n\n\n    Other\n1.37\n0.73, 2.56\n0.3\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.74\n0.55, 1.00\n0.050\n\n\n    South\n0.82\n0.65, 1.04\n0.10\n\n\n    West\n0.92\n0.71, 1.20\n0.5\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n0.87\n0.70, 1.09\n0.2\n\n\n    Small\n0.76\n0.57, 1.01\n0.055\n\n\nHospital location and teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n1.45\n0.85, 2.49\n0.2\n\n\n    Urban, teaching\n1.26\n0.76, 2.09\n0.4\n\n\nCharlson comorbidity index\n1.12\n1.03, 1.23\n0.008\n\n\nAdmission Type\n\n\n\n\n\n\n\n\n    Elective\n—\n—\n\n\n\n\n    Non-elective\n1.10\n0.82, 1.47\n0.5\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n\n\n    CKD, Stage 1\n—\n—\n\n\n\n\n    CKD, Stage 2\n181,951\n105,445, 313,966\n&lt;0.001\n\n\n    CKD, Stage 3\n188,605\n141,280, 251,785\n&lt;0.001\n\n\n    CKD, Stage 4\n441,771\n322,192, 605,730\n&lt;0.001\n\n\n    CKD, Stage 5\n452,828\n231,268, 886,650\n&lt;0.001\n\n\n    ESRD\n580,990\n420,363, 802,996\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.50\n0.35, 0.71\n&lt;0.001\n\n\nDiabetes Mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.80\n0.61, 1.04\n0.10\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.59\n0.45, 0.78\n&lt;0.001\n\n\nChronic Pulmonary Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.83\n0.65, 1.04\n0.11\n\n\nLiver Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3.90\n2.98, 5.12\n&lt;0.001\n\n\nPeripheral Vascular Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.05\n0.80, 1.38\n0.7\n\n\nCongestive Heart Failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.00\n1.55, 2.57\n&lt;0.001\n\n\nMyocardial Infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.87\n1.53, 2.29\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute Kidney Injury:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nPacemaker Type\n\n\n\n\n\n\n\n\n    TV-VVI\n—\n—\n\n\n\n\n    Leadless Pacemaker\n1.15\n1.03, 1.29\n0.013\n\n\nAge, y\n0.99\n0.98, 0.99\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.98\n0.92, 1.04\n0.5\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.41\n1.18, 1.69\n&lt;0.001\n\n\n    Black\n1.04\n0.94, 1.15\n0.4\n\n\n    Hispanic\n1.26\n1.12, 1.42\n&lt;0.001\n\n\n    Native American\n0.83\n0.55, 1.26\n0.4\n\n\n    Other\n1.45\n1.19, 1.78\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.01\n0.92, 1.10\n0.9\n\n\n    $66,000 - $87,999\n0.92\n0.84, 1.01\n0.073\n\n\n    $88,000 or more\n0.97\n0.88, 1.07\n0.6\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.97\n0.78, 1.20\n0.8\n\n\n    Medicare\n0.89\n0.79, 1.00\n0.054\n\n\n    Other\n1.07\n0.85, 1.35\n0.5\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.93\n0.84, 1.03\n0.15\n\n\n    South\n1.04\n0.96, 1.13\n0.4\n\n\n    West\n0.93\n0.84, 1.02\n0.12\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n1.02\n0.95, 1.10\n0.6\n\n\n    Small\n1.02\n0.93, 1.12\n0.7\n\n\nHospital location and teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n1.21\n1.03, 1.43\n0.022\n\n\n    Urban, teaching\n1.23\n1.06, 1.43\n0.008\n\n\nCharlson comorbidity index\n1.02\n0.99, 1.06\n0.2\n\n\nAdmission Type\n\n\n\n\n\n\n\n\n    Elective\n—\n—\n\n\n\n\n    Non-elective\n2.06\n1.87, 2.27\n&lt;0.001\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n\n\n    CKD, Stage 1\n—\n—\n\n\n\n\n    CKD, Stage 2\n1.71\n1.11, 2.64\n0.016\n\n\n    CKD, Stage 3\n2.40\n1.58, 3.66\n&lt;0.001\n\n\n    CKD, Stage 4\n3.95\n2.58, 6.04\n&lt;0.001\n\n\n    CKD, Stage 5\n3.68\n2.21, 6.13\n&lt;0.001\n\n\n    ESRD\n0.37\n0.24, 0.57\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.00\n0.88, 1.15\n&gt;0.9\n\n\nDiabetes Mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.15\n1.05, 1.26\n0.003\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.01\n0.93, 1.09\n0.8\n\n\nChronic Pulmonary Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.92, 1.07\n0.9\n\n\nLiver Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.70\n1.46, 1.98\n&lt;0.001\n\n\nPeripheral Vascular Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.89, 1.09\n0.8\n\n\nCongestive Heart Failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.76\n1.64, 1.89\n&lt;0.001\n\n\nMyocardial Infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.18\n1.09, 1.28\n&lt;0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAny Complication:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nPacemaker Type\n\n\n\n\n\n\n\n\n    TV-VVI\n—\n—\n\n\n\n\n    Leadless Pacemaker\n1.87\n1.62, 2.16\n&lt;0.001\n\n\nAge, y\n0.98\n0.98, 0.99\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.90\n0.81, 0.99\n0.038\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.96\n0.73, 1.26\n0.8\n\n\n    Black\n1.04\n0.89, 1.21\n0.7\n\n\n    Hispanic\n1.00\n0.83, 1.21\n&gt;0.9\n\n\n    Native American\n0.49\n0.19, 1.26\n0.14\n\n\n    Other\n1.04\n0.73, 1.49\n0.8\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.92\n0.80, 1.05\n0.2\n\n\n    $66,000 - $87,999\n0.93\n0.81, 1.07\n0.3\n\n\n    $88,000 or more\n1.00\n0.86, 1.17\n&gt;0.9\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.03\n0.75, 1.41\n0.9\n\n\n    Medicare\n1.03\n0.86, 1.24\n0.7\n\n\n    Other\n1.27\n0.93, 1.74\n0.13\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.80\n0.69, 0.94\n0.007\n\n\n    South\n0.92\n0.81, 1.04\n0.2\n\n\n    West\n0.93\n0.81, 1.07\n0.3\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n0.86\n0.76, 0.97\n0.011\n\n\n    Small\n0.77\n0.66, 0.89\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n0.95\n0.72, 1.26\n0.7\n\n\n    Urban, teaching\n1.29\n1.00, 1.66\n0.047\n\n\nCharlson comorbidity index\n0.98\n0.92, 1.03\n0.4\n\n\nAdmission Type\n\n\n\n\n\n\n\n\n    Elective\n—\n—\n\n\n\n\n    Non-elective\n0.58\n0.51, 0.66\n&lt;0.001\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n\n\n    CKD, Stage 1\n—\n—\n\n\n\n\n    CKD, Stage 2\n0.72\n0.40, 1.31\n0.3\n\n\n    CKD, Stage 3\n0.83\n0.47, 1.46\n0.5\n\n\n    CKD, Stage 4\n0.81\n0.46, 1.45\n0.5\n\n\n    CKD, Stage 5\n1.12\n0.57, 2.18\n0.7\n\n\n    ESRD\n1.22\n0.69, 2.16\n0.5\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.81\n0.66, 1.00\n0.048\n\n\nDiabetes Mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.82\n0.71, 0.95\n0.008\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.88\n0.77, 0.99\n0.039\n\n\nChronic Pulmonary Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.10\n0.97, 1.25\n0.14\n\n\nLiver Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.46\n1.19, 1.79\n&lt;0.001\n\n\nPeripheral Vascular Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.30\n1.13, 1.50\n&lt;0.001\n\n\nCongestive Heart Failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.28\n1.13, 1.44\n&lt;0.001\n\n\nMyocardial Infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.81, 1.06\n0.3\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "In-Hospital Outcomes and Complications of Leadless Versus Traditional Transvenous Pacemaker Implantation in Patients with Chronic Kidney Disease",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nPacemaker Type\n\n\n\n\n\n\n\n\n    TV-VVI\n—\n—\n\n\n\n\n    Leadless Pacemaker\n2.7\n2.0, 3.3\n&lt;0.001\n\n\nAge, y\n-0.10\n-0.12, -0.08\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n-0.35\n-0.57, -0.13\n0.002\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n0.90\n0.10, 1.7\n0.028\n\n\n    Black\n0.73\n0.32, 1.1\n&lt;0.001\n\n\n    Hispanic\n0.62\n0.02, 1.2\n0.041\n\n\n    Native American\n-0.87\n-2.5, 0.72\n0.3\n\n\n    Other\n1.6\n0.37, 2.8\n0.010\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-0.17\n-0.51, 0.17\n0.3\n\n\n    $66,000 - $87,999\n-0.28\n-0.63, 0.06\n0.11\n\n\n    $88,000 or more\n-0.13\n-0.50, 0.25\n0.5\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.57\n-0.86, 2.0\n0.4\n\n\n    Medicare\n-0.85\n-1.4, -0.27\n0.004\n\n\n    Other\n-0.29\n-1.3, 0.67\n0.6\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.67\n0.29, 1.1\n&lt;0.001\n\n\n    South\n0.39\n0.06, 0.72\n0.022\n\n\n    West\n-0.61\n-0.98, -0.24\n0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n-0.90\n-1.2, -0.62\n&lt;0.001\n\n\n    Small\n-1.1\n-1.4, -0.78\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n1.0\n0.52, 1.5\n&lt;0.001\n\n\n    Urban, teaching\n1.7\n1.3, 2.1\n&lt;0.001\n\n\nCharlson comorbidity index\n0.59\n0.42, 0.75\n&lt;0.001\n\n\nAdmission Type\n\n\n\n\n\n\n\n\n    Elective\n—\n—\n\n\n\n\n    Non-elective\n0.64\n0.28, 0.99\n&lt;0.001\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n\n\n    CKD, Stage 1\n—\n—\n\n\n\n\n    CKD, Stage 2\n-0.54\n-2.1, 1.0\n0.5\n\n\n    CKD, Stage 3\n0.00\n-1.5, 1.5\n&gt;0.9\n\n\n    CKD, Stage 4\n0.73\n-0.81, 2.3\n0.4\n\n\n    CKD, Stage 5\n1.4\n-0.51, 3.3\n0.2\n\n\n    ESRD\n2.9\n1.3, 4.5\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.2\n-1.9, -0.47\n0.001\n\n\nDiabetes Mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.5\n-1.9, -1.1\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.21\n-0.49, 0.08\n0.2\n\n\nChronic Pulmonary Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.38\n-0.67, -0.08\n0.012\n\n\nLiver Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.7\n1.8, 3.6\n&lt;0.001\n\n\nPeripheral Vascular Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.14\n-0.50, 0.22\n0.4\n\n\nCongestive Heart Failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.0\n1.7, 2.2\n&lt;0.001\n\n\nMyocardial Infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.20\n-0.15, 0.55\n0.3\n\n\n\nAbbreviation: CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation-adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nPacemaker Type\n\n\n\n\n\n\n\n\n    TV-VVI\n—\n—\n\n\n\n\n    Leadless Pacemaker\n58,461\n44,399, 72,523\n&lt;0.001\n\n\nAge, y\n-2,334\n-2,802, -1,867\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n3,989\n-1,212, 9,190\n0.13\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n29,403\n3,473, 55,333\n0.026\n\n\n    Black\n5,609\n-3,886, 15,104\n0.2\n\n\n    Hispanic\n29,839\n17,183, 42,495\n&lt;0.001\n\n\n    Native American\n-43,751\n-79,645, -7,858\n0.017\n\n\n    Other\n61,472\n32,603, 90,341\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n611\n-7,102, 8,325\n0.9\n\n\n    $66,000 - $87,999\n2,145\n-5,597, 9,887\n0.6\n\n\n    $88,000 or more\n6,523\n-2,413, 15,458\n0.2\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n671\n-24,343, 25,684\n&gt;0.9\n\n\n    Medicare\n-5,731\n-19,677, 8,215\n0.4\n\n\n    Other\n3,205\n-22,181, 28,590\n0.8\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n29,766\n20,630, 38,902\n&lt;0.001\n\n\n    South\n31,975\n24,065, 39,886\n&lt;0.001\n\n\n    West\n67,964\n52,654, 83,275\n&lt;0.001\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n-24,833\n-33,618, -16,048\n&lt;0.001\n\n\n    Small\n-28,480\n-37,720, -19,240\n&lt;0.001\n\n\nHospital location and teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n42,318\n32,764, 51,872\n&lt;0.001\n\n\n    Urban, teaching\n58,348\n50,000, 66,695\n&lt;0.001\n\n\nCharlson comorbidity index\n5,550\n2,417, 8,683\n&lt;0.001\n\n\nAdmission Type\n\n\n\n\n\n\n\n\n    Elective\n—\n—\n\n\n\n\n    Non-elective\n-81,702\n-91,781, -71,624\n&lt;0.001\n\n\nChronic Kidney Disease Stage\n\n\n\n\n\n\n\n\n    CKD, Stage 1\n—\n—\n\n\n\n\n    CKD, Stage 2\n-13,528\n-46,538, 19,483\n0.4\n\n\n    CKD, Stage 3\n-11,882\n-45,781, 22,017\n0.5\n\n\n    CKD, Stage 4\n508\n-33,707, 34,724\n&gt;0.9\n\n\n    CKD, Stage 5\n3,154\n-40,218, 46,526\n0.9\n\n\n    ESRD\n53,244\n16,947, 89,542\n0.004\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-22,978\n-40,899, -5,057\n0.012\n\n\nDiabetes Mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-22,092\n-30,342, -13,841\n&lt;0.001\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-4,550\n-11,561, 2,461\n0.2\n\n\nChronic Pulmonary Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-4,319\n-10,994, 2,355\n0.2\n\n\nLiver Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n59,160\n36,875, 81,446\n&lt;0.001\n\n\nPeripheral Vascular Disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n4,933\n-3,120, 12,985\n0.2\n\n\nCongestive Heart Failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n43,534\n37,086, 49,982\n&lt;0.001\n\n\nMyocardial Infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n16,573\n8,490, 24,657\n&lt;0.001\n\n\n\nAbbreviation: CI = Confidence Interval"
  }
]